Small molecule corticotropin-releasing factor antagonists

Bibliography

• ARBORELIUS L, OWENS MJ, PLOTSKY PM, NEMEROFF CB: The role of corticotropin-releasing factor in depression and anxiety disorders.j Endocrinol (1999) 160:1–12.
   PubMed Web of Science ®Google Scholar
• HOLSBOER F: Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy. j. Affect. Llisord (2001) 62(1-2):77–91.
   PubMed Web of Science ®Google Scholar
• TIMPLE P, SPANAGEL R, SILLAGEL I et al.: Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nature Genet. (1998) 19:162–166.
   PubMed Web of Science ®Google Scholar
• BALE TL, CONTARINO A, SMITH GW et al.: Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nature Genet. (2000) 24(4):410–414.
   PubMed Web of Science ®Google Scholar
• NEMEROFF CB, WIDERLOV E, BISSETTE G et al.: Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science (1984) 226(4680):1342–1344.
   PubMed Web of Science ®Google Scholar
• HOLSBOER F; VON BARDELEBEN U, GERKEN A, STALLA GK, MULLER OA: Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression. N Engl. J. Med. (1984) 311(17):1127.
   PubMed Web of Science ®Google Scholar
• GRIGORIADIS DE, HADDACH M, LING N, SAUNDERS J: The CRF receptor: structure, function and potential for therapeutic intervention. Curt: Med. Chem.-Central Nervous system agents(2001) 1:63–97.
   Google Scholar
• •A concise review of the CRF system including target validation, peptide and receptor structure/function, medicinal chemistry and therapeutic indications.
   Google Scholar
• GILLIGAN PJ, ROBERTSON DW, ZACZEK R: Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents. Med. Chem. (2000) 43(9):1641–1660.
   Web of Science ®Google Scholar
• •A thorough review of CRF medicinal chemistry including in vivo data.
   Google Scholar
• HOLSBOER F: The rational for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety.' Psychiam Res. (1999) 33:181–214.
   PubMed Web of Science ®Google Scholar
• TACHE Y, MARTINEZ V, MILLION M, WANG L: Stress and the gastrointestinal tract III. Stress-related alterations of gut motor function: role of brain corticotropin-releasing factor receptors. Am. j Physiol Gastrointest. Liver Physiol (2001) 280(2):G173–G177.
   Google Scholar
• KOOB G: Neurobiology of addiction. Toward the development of new therapies. Ann. NY Acad. Sci (2000) 909:170–85.
   PubMed Web of Science ®Google Scholar
• LARIVIERE WR, MELZACK R: The role of corticotropin-releasing factor in pain and analgesia. Pain (2000) 84:1–12.
   PubMed Web of Science ®Google Scholar
• SKELTON KH, OWENS MJ, NEMEROFF CB: The neurobiology of urocortin. Regal Pept. (2000) 93(1-3):85–92.
   PubMedGoogle Scholar
• GULLY D, GESLIN M, SERVAL et al: 4-(2-Chloro-4-methoxy-5-methylpheny1)-N-R1.5)-2-cyclopropyl 1 (3 fluoro-4-methylphenyl) ethyl]5-methyl-N- (2- propyny1)-1,3-thiazol-2-amine hydrochloride (55R125543A): a potent and selective corticotropin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization.j Pharmacol Exp. Ther. (2002) 301(1):322–332.
   Google Scholar
• ••A comprehensive report on the in vitrocharacterisation of a thiazole antagonist.
   Google Scholar
• LIAW CW, GRIGORIADIS DE, LORANG MT, DE SOUZA EB, MAKI RA: Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. Ma Endocrinology (1997) 11:2048–2053.
   Web of Science ®Google Scholar
• GRIEBEL G, SIMIAND J, STEINBERG R et al: 4-(2-Chloro-4-methoxy-5-methylpheny1)-N- [03)-2-cyclopropyl 1 (3 fluoro-4- methylphenyl) ethyl] 5-methyl-N- (2-propyny1)-1, 3-thiazol-2-amine hydrochloride (55R125543A), a potent and selective corticotropin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. " Pharmacol Exp. The]: (2002) 301(1):333–345.
   Google Scholar
• ••A thorough in vivo evaluation of a thiazoleantagonist.
   Google Scholar
• CHEN C, DAGNINO R Jr, HUANG CQ, MCCARTHY JR, GRIGORIADIS DE: 1-Alky1-3-amino-5-ary1-1H-[1,2,4]triazoles: novel synthesis via cyclization of N-acyl-S-methylisothioureas with alkylhydrazines and their potent corticotropin-releasing factor-1 (CRF1) receptor antagonist activities. Bioorg. Med. Chem. Lett. (2001) 11(24):3165–3168.
   PubMed Web of Science ®Google Scholar
• KELLER PA, BOWMAN M, DANG KH et al: Pharmacophore development for corticotropin-releasing hormone: new insights into inhibitor activity. j. Med. Chem. (1999) 42:2351–2357.
   PubMed Web of Science ®Google Scholar
• WANG XC, SAUNDERS J: Design and discovery of nonpeptide antagonists for corticotropin-releasing factor receptor: neurocrine multichannel discovery approach. 221st National ACS meeting, San Diego, USA (2001). MEDI 207.
   Google Scholar
• CHEN YL, MANSBACH RS, WINTER SM et al: Synthesis and oral efficacy of a 4- (butylethylamino) pyro lo [2,3D] pyrimidine: A centrally active corticotropin-releasing factorl receptor antagonist.j Med. Chem. (1997) 40:1749–1754.
   PubMed Web of Science ®Google Scholar
• ARVANITIS AG, GILLIGAN PJ, CHORVAT RS et al: nonpeptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines.j. Med. Chem. (1999) 42:805–818.
   PubMed Web of Science ®Google Scholar
• CHEN C, DAGNINO R Jr, DE SOUZA EB et al.: Design and synthesis of a series of nonpeptide high-affinity human corticotropin-releasing factori receptor antagonists. Med. Chem. (1996) 39:4358–4360.
   Google Scholar
• COCUZZA AJ, HOBBS FW, ARNOLD CR et al: 4-aryl-2- anilinopyrimidnes as corticotropin-releasing hormone (CRH) antagonists. Bioorg. Med. Chem. Letters (1999) 9:1057–1062.
   PubMed Web of Science ®Google Scholar
• OKUYAMA S, CHAKI S, KAWASHIMA N et al.: Receptor binding, behavioural and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. Pharmacol. Exp. The]: (1999) 289(2):926–935.
   PubMed Web of Science ®Google Scholar
• •Extensive in vivo characterisation of a monocydic antagonist.
   Google Scholar
• GILLIGAN PJ, HE L, CULP S, FITZGERALD L, TAM SW, WONG YN: Structure-activity studies on 4-substituted-2-anilinopyrimidine corticotropin releasing factor (CRF) antagonists. Bioorg. Med. Chem. (1999) 7:2321–2328.
   PubMed Web of Science ®Google Scholar
• HODGE CN, ALDRICH PE, WASSERMAN ZR et al: Corticotropin-releasing hormone receptor antagonists: framework design and synthesis guided by ligand conformational studies. I Med. Chem. (1999) 42:819–832.
   PubMed Web of Science ®Google Scholar
• •Small molecule structural studies that led to the rational design of bicyclic antagonists.
   Google Scholar
• HSIN LW, TIAN X, WEBSTER EL et al.: CRHRi receptor binding and lipophilicity of pyrrolpyrimidines, potential nonpeptide corticotropin-releasing hormone Type 1 receptor antagonists. Bioorg. Med. Chem. (2002) 10:175–183.
   PubMed Web of Science ®Google Scholar
• •Addesses issues of high logP values and identifies the new top region side chains in antalarmin analogues.
   Google Scholar
• WILSON DM, TERMIN AP, MAO Let al.: Arylamidrazones as novel corticotropin releasing factor receptor antagonists. .1 Med. Chem. (2002) 45(11):2123–2126.
   Google Scholar
• VALE W, SPEISS J, RIVIER C, RIVIERJ: Characterization of a 41 residue ovine hypothalamic peptide that stimulates secretion of corticotropin and 13 endorphin. Science (1981) 213 (4514):1394–1397.
   PubMed Web of Science ®Google Scholar
• REYES TM, LEWIS K, PERRIN MH et al.: Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by Type 2 CRF receptors. Proc. Nati Acad. Sci. USA (2001) 98(5):2843–2848.
   PubMed Web of Science ®Google Scholar
• RUHMANN A, BONK I, LIN CR, ROSENFELD MG, SPIESS J: Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR213-selective antisauvagine-30. Proc. Nati Acad. Sci. USA. (1998) 95(26):15264–15269.
   PubMed Web of Science ®Google Scholar
• HSU SY, HSUEH AJ: Human stresscopin and stresscopin-related peptide are selective ligands for the Type 2 corticotropin-releasing hormone receptor. Nat. Med. (2001) 7(5):605–611.
   PubMed Web of Science ®Google Scholar
• OWENS MJ, NEMEROFF CB: Corticotropin-releasing factor antagonists. Therapeutic potential in the treatment of affective disorders. CNS drugs (1999) 12(2):85–92.
   Google Scholar
• KECK ME, WELT T, WIGGER A et al.: The amdolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats. Eur: j Neurosci. (2001) 13(2):373–380.
   PubMed Web of Science ®Google Scholar
• ZOBEL AW, NICKEL T, KUNZEL HE et al.: Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. j Psychiatr. Res. (2000) 34(3):171–181.
   PubMed Web of Science ®Google Scholar
• ••The only report of clinical data for a CRP'antagonist.
   Google Scholar